{
    "clinical_study": {
        "@rank": "60494", 
        "arm_group": {
            "arm_group_label": "Herceptin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This single-arm, open-label, local multicenter study will evaluate the safety and\n      tolerability of Herceptin (trastuzumab) administered subcutaneously by a single-use\n      injection device (SID) in patients with HER2-positive early breast cancer. Following surgery\n      (and neo-adjuvant or adjuvant chemotherapy), patients will receive Herceptin 600 mg\n      subcutaneously by SID every 3 weeks for a total of 1 year, unless disease recurrence or\n      unacceptable toxicity occurs. After the first 3 cycles, patients will be permitted to\n      self-administer Herceptin under supervision of a HCP."
        }, 
        "brief_title": "A Study of Subcutaneous Herceptin (Trastuzumab) Administered at Home By Single-Use Injection Device in Patients With Early HER2-Positive Breast Cancer (HOMERUS)", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female and male patients, >/= 18 years of age\n\n          -  Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast\n\n          -  HER2-positive disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  Hormonal therapy will be allowed as per institutional guidelines\n\n          -  Prior use of anti-HER2 therapy will be allowed except for early breast cancer\n             patients in the neo-adjuvant setting\n\n          -  Left ventricular ejection fraction >/= 55%\n\n          -  No evidence of residual, locally recurrent or metastatic disease after completion of\n             surgery and chemotherapy, or during concurrent chemotherapy (neo-adjuvant or\n             adjuvant)\n\n          -  Use of concurrent radiotherapy will be permitted\n\n          -  Completion of surgery and chemotherapy (if applicable) for early breast cancer\n\n        Exclusion Criteria:\n\n          -  History of other malignancy, except for patients with curatively treated carcinoma in\n             situ of the cervix or basal cell carcinoma and patients with other curatively treated\n             malignancies who have been disease-free for the last 5 years\n\n          -  Patients with severe dyspnea at rest or requiring supplementary oxygen therapy\n\n          -  Patients with other concurrent serious diseases that might interfere with planned\n             treatment, including severe pulmonary conditions/illness\n\n          -  Serious cardiac illness or medical conditions that would preclude the use of\n             trastuzumab, specifically: history of documented congestive heart failure, high-risk\n             uncontrolled arrhythmias, angina pectoris requiring medication, clinically\n             significant valvular disease, evidence of transmural infarction on ECG, poorly\n             controlled hypertension\n\n          -  Pregnant or lactating women\n\n          -  Women of childbearing potential and male patients with female partners of\n             childbearing potential who are unable or unwilling to use adequate contraceptive\n             methods during study treatment\n\n          -  Concurrent enrolment in another clinical trial using an investigational anti-cancer\n             treatment, including hormonal therapy, biphosphonate therapy and immunotherapy,\n             within 28 days prior to the first dose of study treatment\n\n          -  Known hypersensitivity to trastuzumab, murine proteins, to any excipients of\n             Herceptin including hyaluronidase, or the adhesive of the SC device, or a history of\n             severe allergic or immunological reactions, e.g. difficult to control asthma\n\n          -  Inadequate bone marrow, hepatic or renal function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "128", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040935", 
            "org_study_id": "ML28878", 
            "secondary_id": "2013-000829-31"
        }, 
        "intervention": {
            "arm_group_label": "Herceptin", 
            "description": "600 mg subcutaneously every 3 weeks by single-use injection device", 
            "intervention_name": "trastuzumab [Herceptin]", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 17, 2014", 
        "number_of_arms": "1", 
        "official_title": "HOMERUS: A LOCAL OPEN LABEL, MULTICENTRE, PHASE IIIB STUDY, INVESTIGATING SUBCUTANEOUS TRASTUZUMAB ADMINISTERED AT HOME WITH SINGLE INJECTION DEVICE IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28878 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Centrale Commissie Mensgebonden Onderzoek (CCMO)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence and severity of adverse events and serious adverse events by NCI CTAE version 4-0", 
            "safety_issue": "No", 
            "time_frame": "approximately 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040935"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Trough concentrations (Ctrough) of trastuzumab following in-hospital and in-home administration via SID", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose Cycles 2, 3, 9, and 10 or 13 (Weeks 4, 7, 25, and 28 or 32)"
            }, 
            {
                "measure": "Patient reported health/mental status assessed by questionnaire (SF-36 and MASQ)", 
                "safety_issue": "No", 
                "time_frame": "28 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}